ResMed Inc. (ASX:RMD)

Market Cap	52.40B -5.5%
Revenue (ttm)	8.09B +9.6%
Net Income	2.23B +19.0%
EPS	15.16 +19.4%
Shares Out	n/a
PE Ratio	23.52
Forward PE	22.04
Dividend	0.35 (0.97%)
Ex-Dividend Date	Feb 11, 2026

Volume	1,115,084
Average Volume	1,496,292
Open	36.03
Previous Close	35.58
Day's Range	36.03 - 36.43
52-Week Range	32.04 - 45.25
Beta	0.88
RSI	47.26
Earnings Date	Apr 23, 2026

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1989
• Employees: 10,600
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RMD

Financial Performance

In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.

Financial numbers in USD